|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr 8:55,401,981...55,415,012
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein] |
CTD RGD |
PMID:9454827 PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions increases response to substance increases activity |
ISO |
Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein] CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein |
CTD |
PMID:10082212 PMID:10216184 |
|
NCBI chr 1:116,715,286...116,837,223
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein] |
CTD RGD |
PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] |
CTD |
PMID:9454827 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Tnf |
tumor necrosis factor |
increases activity |
EXP |
TNF results in increased activity of Dimethylphenylpiperazinium Iodide |
CTD |
PMID:15086448 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
affects binding |
IDA |
4-DAMP methiodide inhibits response to acetylcholine in rat aortic rings |
RGD |
PMID:8075871 |
RGD:2303390 |
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Ambenonium Chloride results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
App |
amyloid beta precursor protein |
affects cleavage |
EXP |
Ambenonium Chloride affects the cleavage of APP protein |
CTD |
PMID:11099780 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AACS mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ABCA1 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abca12 |
ATP binding cassette subfamily A member 12 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ABCA12 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 9:72,822,661...72,995,748
Ensembl chr 9:72,823,350...72,996,049
|
|
G |
Abca6 |
ATP binding cassette subfamily A member 6 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ABCA6 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr10:95,142,805...95,212,087
Ensembl chr10:95,142,966...95,211,530
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACOD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:79,871,819...79,881,101
Ensembl chr15:79,871,827...79,880,529
|
|
G |
Acp6 |
acid phosphatase 6, lysophosphatidic |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACP6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:184,711,975...184,733,067
Ensembl chr 2:184,711,619...184,733,017
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACSL4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Ada |
adenosine deaminase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ADA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adh1 |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ADH1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adora1 |
adenosine A1 receptor |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ADORA1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:112,119,673...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AKR1B10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ALB mRNA |
CTD |
PMID:31199489 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOA1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apoc1 |
apolipoprotein C1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AQP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AREG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ARG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ART3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr14:15,637,230...15,719,442
Ensembl chr14:15,637,237...15,665,407
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATF4 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atp5f1e |
ATP synthase F1 subunit epsilon |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATP5E mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450
|
|
G |
Atp5mg |
ATP synthase membrane subunit g |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATP5L mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:45,226,750...45,233,582
Ensembl chr 8:45,225,686...45,233,559
|
|
G |
B3galt4 |
Beta-1,3-galactosyltransferase 4 |
affects response to substance |
ISO |
B3GALT4 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,936,089...4,937,664
Ensembl chr20:4,931,768...4,938,315
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of BAMBI mRNA |
CTD |
PMID:20146380 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of BCL3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Btc |
betacellulin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of BTC mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:16,708,447...16,746,961
Ensembl chr14:16,707,982...16,747,049
|
|
G |
C1s |
complement C1s |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Benzalkonium Compounds analog results in increased cleavage of CASP3 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of CASP3 protein] |
CTD |
PMID:31982400 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CASP8 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL11 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression increases secretion |
ISO |
Benzalkonium Compounds results in increased expression of CCL2 mRNA; Benzalkonium Compounds results in increased expression of CCL2 protein Benzalkonium Compounds results in increased secretion of CCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31707104 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL20 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCL24 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CCL3 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression multiple interactions increases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCL4 mRNA; Benzalkonium Compounds results in decreased expression of CCL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein Benzalkonium Compounds results in increased expression of CCL4 protein |
CTD |
PMID:18353026 PMID:20713136 PMID:30517752 PMID:31158415 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL7 mRNA; Benzalkonium Compounds results in increased expression of CCL7 protein |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCN2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccn3 |
cellular communication network factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCN3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCR4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:114,176,256...114,182,155
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCR5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Cd177 |
CD177 molecule |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:227,116,627...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd300c2 |
CD300C molecule 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CD300C2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:100,253,312...100,258,553
Ensembl chr10:100,253,624...100,258,323
|
|
G |
Cfap61 |
cilia and flagella associated protein 61 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CFAP61 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 3:133,354,400...133,633,310
Ensembl chr 3:133,354,197...133,633,320
|
|
G |
Cfd |
complement factor D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CFD mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CHIL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CHRNB4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CLCF1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Cnfn |
cornifelin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CNFN mRNA; Benzalkonium Compounds results in increased expression of CNFN protein |
CTD |
PMID:25377654 |
|
NCBI chr 1:80,949,699...80,953,747
Ensembl chr 1:80,951,600...80,953,747
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF1 protein |
CTD |
PMID:30517752 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF2 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF3 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Ctps1 |
CTP synthase 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL10 mRNA; Benzalkonium Compounds results in increased expression of CXCL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein |
CTD |
PMID:23445166 PMID:30517752 PMID:31158415 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL2 mRNA; Benzalkonium Compounds results in increased expression of CXCL2 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31158415 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA Benzalkonium Compounds results in increased expression of CXCL1 protein; Benzalkonium Compounds results in increased expression of CXCL3 mRNA |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
multiple interactions increases expression |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA Benzalkonium Compounds results in increased expression of CXCL5 mRNA; Benzalkonium Compounds results in increased expression of CXCL5 protein |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr14:17,310,089...17,312,303
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CXCR1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 9:75,768,124...75,771,122
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CXCR4 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression increases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CYP1A1 mRNA Benzalkonium Compounds results in increased expression of CYP1A1 mRNA |
CTD |
PMID:20713136 PMID:30806763 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CYP51 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DHCR24 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:121,344,637...121,368,853
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases activity increases expression |
ISO |
Benzalkonium Compounds results in decreased activity of DHCR7 protein Benzalkonium Compounds results in increased expression of DHCR7 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of DLK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DUSP1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EBP mRNA |
CTD |
PMID:26919959 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of EGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EGR1 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELF3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELOVL1 mRNA |
CTD |
PMID:29155129 |
|
NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELOVL6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Endou |
endonuclease, poly(U)-specific |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ENDOU mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:128,845,862...128,866,542
Ensembl chr 7:128,844,862...128,866,596
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ENO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Etnk1 |
ethanolamine kinase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ETNK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770
|
|
G |
Exo1 |
exonuclease 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EXO1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Ezr |
ezrin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EZR mRNA; Benzalkonium Compounds results in increased expression of EZR protein |
CTD |
PMID:29893927 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fam83a |
family with sequence similarity 83, member A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FAM83A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:89,522,826...89,547,284
Ensembl chr 7:89,522,826...89,547,388
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance |
ISO |
FGF2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FGR mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326
|
|
G |
Flg |
filaggrin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FLG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,888,688...178,912,731
|
|
G |
Foxc1 |
forkhead box C1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803
|
|
G |
Foxn1 |
forkhead box N1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:63,251,400...63,273,710
Ensembl chr10:63,251,400...63,273,710
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GCLC mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GCLM mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GPX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HBEGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HIF1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HMGCR mRNA |
CTD |
PMID:26919959 PMID:31199489 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HMGCS2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hoxa7 |
homeobox A7 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of HOXA7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:81,315,730...81,317,629
Ensembl chr 4:81,314,625...81,317,659
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HSD17B7 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of HSPA5 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ICAM1 mRNA; Benzalkonium Compounds results in increased expression of ICAM1 protein |
CTD |
PMID:21742781 PMID:30806763 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IDI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IFNG protein |
CTD |
PMID:30517752 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO |
Benzalkonium Compounds results in increased expression of and results in decreased secretion of IL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein Benzalkonium Compounds results in increased expression of IL10 protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13ra2 |
interleukin 13 receptor subunit alpha 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL13RA2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381
|
|
G |
Il15 |
interleukin 15 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL15 protein |
CTD |
PMID:30517752 |
|
NCBI chr19:25,640,013...25,706,818
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il17f |
interleukin 17F |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL17F mRNA |
CTD |
PMID:23445166 |
|
NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL18 protein Benzalkonium Compounds results in increased expression of IL18 mRNA |
CTD |
PMID:30517752 PMID:30806763 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
increases secretion multiple interactions increases expression |
ISO |
Benzalkonium Compounds results in increased secretion of IL1A protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A mRNA; Benzalkonium Compounds results in increased expression of IL1A protein |
CTD |
PMID:8006454 PMID:12781210 PMID:25290854 PMID:30240708 PMID:30517752 PMID:31158415 More...
|
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of IL1B protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1f10 |
interleukin 1 family member 10 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:7,072,511...7,075,439
Ensembl chr 3:7,072,511...7,075,439
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL23A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il27 |
interleukin 27 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL27 protein |
CTD |
PMID:30517752 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il3 |
interleukin 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL3 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il31 |
interleukin 31 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL31 protein |
CTD |
PMID:30517752 |
|
NCBI chr12:33,095,108...33,105,026
Ensembl chr12:33,092,097...33,105,037
|
|
G |
Il31ra |
interleukin 31 receptor A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of IL31RA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:44,118,748...44,189,943
Ensembl chr 2:44,122,624...44,183,767
|
|
G |
Il34 |
interleukin 34 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of IL34 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:38,714,990...38,782,749
Ensembl chr19:38,714,991...38,764,000
|
|
G |
Il36a |
interleukin 36, alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:6,996,851...7,001,400
Ensembl chr 3:6,996,851...7,001,400
|
|
G |
Il36b |
interleukin 36, beta |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:7,024,862...7,122,489
Ensembl chr 3:7,021,973...7,031,619
|
|
G |
Il36g |
interleukin 36, gamma |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:6,948,323...6,954,485
Ensembl chr 3:6,948,297...6,954,480
|
|
G |
Il4 |
interleukin 4 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of IL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions affects response to substance increases expression |
ISO |
Benzalkonium Compounds results in increased secretion of IL6 protein [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of IL6 mRNA; Benzalkonium Compounds results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of and results in increased secretion of IL6 protein |
CTD |
PMID:17763283 PMID:28214551 PMID:29953848 PMID:30171875 PMID:30517752 PMID:31158415 PMID:31707104 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6r |
interleukin 6 receptor |
multiple interactions increases response to substance |
ISO |
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein |
CTD |
PMID:31158415 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL7R mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of INHBA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of INSIG1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Isl1 |
ISL LIM homeobox 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ISL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Benzalkonium Compounds results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdm8 |
lysine demethylase 8 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of KDM8 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:180,013,969...180,028,829
Ensembl chr 1:180,020,656...180,028,841
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of KLK8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
|
|
G |
Krt2 |
keratin 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:132,941,275...132,947,963
Ensembl chr 7:132,940,862...132,947,963
|
|
G |
Krtap14 |
keratin associated protein 14 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:28,126,660...28,127,502
Ensembl chr11:28,126,660...28,127,502
|
|
G |
Lce3e |
late cornified envelope 3E |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LCE3C mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,579,162...178,579,458
Ensembl chr 2:178,579,162...178,579,458
|
|
G |
Ldha |
lactate dehydrogenase A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LDHA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LDLR mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LIF protein |
CTD |
PMID:30517752 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
LOC102551406 |
keratin-associated protein 20-2-like |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:28,412,307...28,412,508
Ensembl chr11:28,481,578...28,481,748
|
|
G |
LOC102552326 |
late cornified envelope protein 5A-like |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LCE1M mRNA |
CTD |
PMID:30171875 |
|
Ensembl chr 2:178,275,020...178,275,469
|
|
G |
Loxl1 |
lysyl oxidase-like 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LOXL1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:58,692,592...58,716,356
Ensembl chr 8:58,692,593...58,716,356
|
|
G |
Lst1 |
leukocyte specific transcript 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LST1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997
|
|
G |
Ltb |
lymphotoxin beta |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases phosphorylation |
ISO |
Benzalkonium Compounds results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:15737199 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mesp2 |
mesoderm posterior bHLH transcription factor 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MESP2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases secretion |
ISO |
Benzalkonium Compounds results in increased secretion of MIF protein |
CTD |
PMID:31707104 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MMP10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MMP12 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp25 |
matrix metallopeptidase 25 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MSMO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Msx2 |
msh homeobox 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879
|
|
G |
Mt2A |
metallothionein 2A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MT2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mylk3 |
myosin light chain kinase 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:21,685,085...21,743,587
Ensembl chr19:21,691,929...21,742,954
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of NDUFA4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of NR4A2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nrg2 |
neuregulin 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:27,619,635...27,798,505
Ensembl chr18:27,619,661...27,798,505
|
|
G |
Ntrk3 |
neurotrophic receptor tyrosine kinase 3 |
affects response to substance |
ISO |
NTRK3 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286
|
|
G |
Ocln |
occludin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of OCLN protein |
CTD |
PMID:29514330 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ODC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Odf3l2 |
outer dense fiber of sperm tails 3-like 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ODF3L2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:10,049,472...10,065,626
Ensembl chr 7:10,059,589...10,065,125
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of OLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Orm1 |
orosomucoid 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ORM1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Benzalkonium Compounds analog results in increased cleavage of PARP1 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of PARP1 protein] |
CTD |
PMID:31982400 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pbk |
PDZ binding kinase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PBK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PCSK9 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pdcd1 |
programmed cell death 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:94,418,786...94,431,945
Ensembl chr 9:94,418,791...94,431,937
|
|
G |
Pfdn6 |
prefoldin subunit 6 |
affects response to substance |
ISO |
PFDN6 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,945,959...4,947,433
Ensembl chr20:4,945,959...4,947,433
|
|
G |
Pglyrp3 |
peptidoglycan recognition protein 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PGLYRP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,479,693...177,490,867
Ensembl chr 2:177,477,407...177,490,736
|
|
G |
Pgp |
phosphoglycolate phosphatase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PGP mRNA |
CTD |
PMID:31199489 |
|
NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Pla2g5 |
phospholipase A2, group V |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PLA2G5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Plcxd3 |
phosphatidylinositol-specific phospholipase C, X domain containing 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PLCXD3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:53,567,022...53,746,384
Ensembl chr 2:53,567,022...53,746,384
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PNPLA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Polr1d |
RNA polymerase I and III subunit D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of POLR1D mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:7,970,592...8,004,157
Ensembl chr12:7,970,595...8,005,624
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PPARA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PRKAA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkag2 |
protein kinase AMP-activated non-catalytic subunit gamma 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PRKAG2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:10,010,574...10,252,152
Ensembl chr 4:10,010,890...10,252,142
|
|
G |
Prokr2 |
prokineticin receptor 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:119,624,738...119,639,442
Ensembl chr 3:119,627,601...119,635,718
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PTGS2 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Reg1a |
regenerating family member 1 alpha |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:110,892,451...110,895,115
Ensembl chr 4:110,892,453...110,895,570
|
|
G |
Reg3g |
regenerating family member 3 gamma |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rgl2 |
ral guanine nucleotide dissociation stimulator-like 2 |
affects response to substance |
ISO |
RGL2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,948,495...4,956,774
Ensembl chr20:4,948,497...4,969,911
|
|
G |
Rps18 |
ribosomal protein S18 |
affects response to substance |
ISO |
RPS18 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,931,427...4,935,538
Ensembl chr10:101,204,500...101,205,146 Ensembl chr20:101,204,500...101,205,146
|
|
G |
RT1-DOa |
RT1 class II, locus DOa |
affects response to substance |
ISO |
HLA-DOA SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577
|
|
G |
RT1-DOb |
RT1 class II, locus DOb |
affects response to substance |
ISO |
HLA-DOB SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,619,599...4,625,627
Ensembl chr20:4,619,816...4,625,667
|
|
G |
RT1-Ha |
RT1 class II, locus Ha |
affects response to substance |
ISO |
HLA-DPA1 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244
|
|
G |
Ryr1 |
ryanodine receptor 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:84,292,578...84,423,799
Ensembl chr 1:84,292,578...84,423,812
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression decreases expression |
ISO |
Benzalkonium Compounds results in increased expression of SCD mRNA Benzalkonium Compounds results in decreased expression of SCD1 mRNA |
CTD |
PMID:29155129 PMID:31199489 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpinb13 |
serpin family B member 13 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:23,118,584...23,150,760
Ensembl chr13:23,118,584...23,150,760
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SERPINE1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SESN2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SFN mRNA |
CTD |
PMID:30171875 |
|
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sfrp4 |
secreted frizzled-related protein 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SFRP4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:45,278,867...45,330,806
Ensembl chr17:45,234,097...45,330,736
|
|
G |
Siglec8 |
sialic acid binding Ig-like lectin 8 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:94,092,737...94,103,134
Ensembl chr 1:94,093,395...94,103,034
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SLC16A1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SLC7A11 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Sox21 |
SRY-box transcription factor 21 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:95,292,272...95,295,316
Ensembl chr15:95,292,265...95,296,091
|
|
G |
Sprr1a |
small proline-rich protein 1A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063
|
|
G |
Sprr1b |
small proline-rich protein 1B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR1B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:178,009,130...178,009,567
Ensembl chr 2:178,009,130...178,009,567
|
|
G |
Sprr2b |
small proline rich protein 2B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,852,824...177,853,096
Ensembl chr 2:177,852,824...177,853,096
|
|
G |
Sprr2f |
small proline rich protein 2F |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2F mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:177,989,974...177,990,204
Ensembl chr 2:177,989,974...177,990,204
|
|
G |
Sqle |
squalene epoxidase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SQLE mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SREBF2 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Srms |
src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:168,318,511...168,324,915
Ensembl chr 3:168,318,512...168,324,915
|
|
G |
St14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:29,540,805...29,581,704
Ensembl chr 8:29,540,811...29,581,517
|
|
G |
Tapbp |
TAP binding protein |
affects response to substance |
ISO |
TAPBP SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,956,937...4,966,191
Ensembl chr20:4,956,937...4,966,181
|
|
G |
Tfap2b |
transcription factor AP-2 beta |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:21,786,250...21,815,785
Ensembl chr 9:21,786,258...21,814,520
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TGFB1 protein |
CTD |
PMID:30517752 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgm3 |
transglutaminase 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TGM3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:117,228,661...117,264,078
Ensembl chr 3:117,228,661...117,264,075
|
|
G |
Tgm7 |
transglutaminase 7 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TGM7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:108,051,890...108,068,116
Ensembl chr 3:108,051,890...108,076,239
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of THBS1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:105,056,286...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases activity |
ISO |
Benzalkonium Compounds results in increased activity of TLR4 protein |
CTD |
PMID:29514330 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tmprss11b |
transmembrane serine protease 11B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TMPRSS11B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:21,385,924...21,405,894
Ensembl chr14:21,383,862...21,408,817
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion increases expression |
ISO |
Benzalkonium Compounds results in decreased secretion of TNF protein Benzalkonium Compounds results in increased expression of TNF mRNA; Benzalkonium Compounds results in increased expression of TNF protein |
CTD |
PMID:29953848 PMID:30171875 PMID:30517752 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf13c |
TNF receptor superfamily member 13C |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:113,736,046...113,738,523
Ensembl chr 7:113,736,055...113,738,517
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:77,253,881...77,277,078
Ensembl chr 5:77,251,373...77,277,421
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TP53 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TPI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Trem2 |
triggering receptor expressed on myeloid cells 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TREM2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:12,647,605...12,654,190
Ensembl chr 9:12,647,259...12,654,170
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Upk3b |
uroplakin 3B |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of UPK3B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:20,629,491...20,638,193
Ensembl chr12:20,631,525...20,637,724
|
|
G |
Uqcrq |
ubiquinol-cytochrome c reductase, complex III subunit VII |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of UQCRQ mRNA |
CTD |
PMID:31199489 |
|
NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of VEGFD mRNA |
CTD |
PMID:20146380 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vtcn1 |
V-set domain containing T cell activation inhibitor 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:188,253,594...188,321,658
Ensembl chr 2:188,253,594...188,321,658
|
|
G |
Wdr46 |
WD repeat domain 46 |
affects response to substance |
ISO |
WDR46 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr20:4,937,845...4,945,796
Ensembl chr20:4,937,847...4,946,535
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of XBP1 mRNA alternative form |
CTD |
PMID:28236482 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xcl1 |
X-C motif chemokine ligand 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of XCL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:77,248,865...77,252,308
Ensembl chr13:77,248,717...77,252,329
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL3 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Benzethonium results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Benzethonium results in decreased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Benzethonium results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Kcna3 |
potassium voltage-gated channel subfamily A member 3 |
decreases activity multiple interactions |
ISO |
Benzethonium results in decreased activity of KCNA3 protein [Benzethonium results in decreased activity of KCNA3 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 |
|
NCBI chr 2:194,632,360...194,633,937
Ensembl chr 2:194,632,196...194,650,138
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
[Benzethonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 PMID:23313619 PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Benzethonium inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Benzethonium results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Bretylium Tosylate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Butylscopolammonium Bromide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Chlormequat promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:25684042 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
EXP |
Chlormequat results in decreased expression of BGLAP protein |
CTD |
PMID:28214531 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of CYP11A1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Gh1 |
growth hormone 1 |
increases expression |
EXP |
Chlormequat results in increased expression of GH1 protein |
CTD |
PMID:31704167 PMID:32622971 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghr |
growth hormone receptor |
decreases expression |
EXP |
Chlormequat results in decreased expression of GHR mRNA |
CTD |
PMID:28214531 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Ghrh |
growth hormone releasing hormone |
increases expression |
EXP |
Chlormequat results in increased expression of GHRH protein |
CTD |
PMID:32622971 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
increases expression |
EXP |
Chlormequat results in increased expression of GNRH1 protein |
CTD |
PMID:29447956 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression |
EXP |
Chlormequat results in decreased expression of HSD3B1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression increases expression |
EXP |
Chlormequat affects the expression of IGF1 protein Chlormequat results in increased expression of IGF1 protein |
CTD |
PMID:28214531 PMID:31704167 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression |
EXP |
Chlormequat results in increased expression of LHB protein |
CTD |
PMID:29447956 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
Chlormequat results in decreased expression of STAR protein |
CTD |
PMID:29447956 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
affects expression |
EXP |
Chlormequat affects the expression of TNFSF11 mRNA |
CTD |
PMID:28214531 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Crp |
C-reactive protein |
decreases expression |
ISO |
Colesevelam Hydrochloride results in decreased expression of CRP protein |
CTD |
PMID:16616026 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
ISO |
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Colesevelam Hydrochloride results in increased expression of HMGCR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Colesevelam Hydrochloride results in increased expression of LDLR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of ACHE protein |
CTD |
PMID:16978018 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Echothiophate Iodide binds to ALB protein |
CTD |
PMID:15525694 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity multiple interactions |
ISO |
Echothiophate Iodide results in decreased activity of BCHE protein Echothiophate Iodide inhibits the reaction [BCHE protein results in increased hydrolysis of Butyrylthiocholine] |
CTD |
PMID:7377577 PMID:16213467 PMID:17698511 PMID:21802514 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Nceh1 |
neutral cholesterol ester hydrolase 1 |
decreases activity |
ISO |
Echothiophate Iodide results in decreased activity of NCEH1 protein |
CTD |
PMID:16978018 |
|
NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588
|
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
Hexamethonium promotes the reaction [Dexamethasone results in increased activity of AVP protein] |
CTD |
PMID:3346065 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects response to substance |
ISO |
BDKRB2 affects the susceptibility to Hexamethonium |
CTD |
PMID:10614985 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
Hexamethonium affects the reaction [Nicotine results in increased expression of BIRC5 protein] |
CTD |
PMID:16601104 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [Nicotine results in decreased expression of CDK4 protein] |
CTD |
PMID:15231866 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
EXP |
Hexamethonium results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] |
CTD |
PMID:9687574 |
|
NCBI chr 8:55,401,981...55,415,012
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] |
CTD |
PMID:7756618 PMID:14645658 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein] |
CTD |
PMID:7756618 PMID:14645658 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
EXP |
Hexamethonium results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] |
CTD |
PMID:9687574 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Hexamethonium inhibits the reaction [Hydrochloric Acid results in increased expression of FOS protein] |
CTD |
PMID:12588467 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein] |
CTD |
PMID:29501575 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Npy |
neuropeptide Y |
multiple interactions |
EXP |
Hexamethonium inhibits the reaction [Nicotine results in increased expression of NPY mRNA] |
CTD |
PMID:2233698 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein] Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form] |
CTD |
PMID:18448488 PMID:20106947 PMID:29501575 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
Hexamethonium affects the reaction [Nicotine results in increased expression of XIAP protein] |
CTD |
PMID:16601104 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases response to substance |
ISO |
Cyclosporine inhibits the reaction [[AHR protein results in increased susceptibility to Antigens] which results in increased susceptibility to Methacholine Chloride] [AHR protein results in increased susceptibility to Antigens] which results in increased susceptibility to Methacholine Chloride; AHR protein results in increased susceptibility to Methacholine Chloride |
CTD |
PMID:27869817 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
multiple interactions |
ISO |
BMPR2 protein affects the susceptibility to [Methacholine Chloride co-treated with Antigens, Dermatophagoides] |
CTD |
PMID:22427841 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
C3 protein affects the susceptibility to [Ozone co-treated with Methacholine Chloride] |
CTD |
PMID:14701711 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
multiple interactions |
EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Atropine inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Calcium inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Heparin affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]; Ro 31-8425 inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]] |
CTD |
PMID:12663092 |
|
NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Methacholine Chloride promotes the reaction [CFTR protein results in increased export of Chlorides]]; Methacholine Chloride promotes the reaction [CFTR protein results in increased export of Chlorides] |
CTD |
PMID:20675434 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cpe |
carboxypeptidase E |
increases response to substance |
ISO |
CPE gene mutant form results in increased susceptibility to Methacholine Chloride |
CTD |
PMID:16002559 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
multiple interactions |
ISO |
Ozone promotes the reaction [CXCR2 protein affects the susceptibility to Methacholine Chloride] |
CTD |
PMID:15361358 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G |
Fcer2 |
Fc epsilon receptor II |
increases expression |
ISO |
Methacholine Chloride results in increased expression of FCER2 protein |
CTD |
PMID:15801332 |
|
NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476
|
|
G |
Grk3 |
G protein-coupled receptor kinase 3 |
affects response to substance |
ISO |
GRK3 mutant form affects the susceptibility to Methacholine Chloride |
CTD |
PMID:10198406 |
|
NCBI chr12:43,624,778...43,735,375
Ensembl chr12:43,624,897...43,731,262
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions increases expression |
ISO |
IL1RN protein results in decreased susceptibility to [Ozone co-treated with Methacholine Chloride] Methacholine Chloride results in increased expression of IL1RN protein |
CTD |
PMID:14754758 PMID:15801332 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Lep |
leptin |
increases response to substance |
ISO |
LEP gene mutant form results in increased susceptibility to Methacholine Chloride |
CTD |
PMID:12794034 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
NOS2 protein affects the reaction [2-chloroethyl ethyl sulfide affects the susceptibility to Methacholine Chloride] |
CTD |
PMID:22446026 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases response to substance |
ISO |
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [NOS3 gene mutant form results in decreased susceptibility to Methacholine Chloride] |
CTD |
PMID:22421449 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
NR1I2 protein affects the susceptibility to [5-alpha-Dihydroprogesterone co-treated with Methacholine Chloride] |
CTD |
PMID:17159084 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride; Chlorpromazine inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]; Cromolyn Sodium inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride] |
CTD |
PMID:22414385 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases response to substance |
ISO |
TNFRSF1A protein results in increased susceptibility to Methacholine Chloride |
CTD |
PMID:21070800 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Trpc3 |
transient receptor potential cation channel, subfamily C, member 3 |
increases activity |
ISO |
Methacholine Chloride results in increased activity of TRPC3 protein |
CTD |
PMID:16522635 |
|
NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855
|
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
trioctylmethylammonium results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
trioctylmethylammonium results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases activity |
ISO |
trioctylmethylammonium results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
trioctylmethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
affects binding |
ISO |
Tiotropium Bromide binds to CHRM1 protein |
CTD |
PMID:21870878 |
|
NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
affects binding |
ISO |
Tiotropium Bromide binds to CHRM2 protein |
CTD |
PMID:21870878 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
affects binding |
ISO |
Tiotropium Bromide binds to CHRM3 protein |
CTD |
PMID:21870878 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
affects binding |
ISO |
Tiotropium Bromide binds to CHRM4 protein |
CTD |
PMID:21870878 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
affects binding |
ISO |
Tiotropium Bromide binds to CHRM5 protein |
CTD |
PMID:21870878 |
|
NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
Tiotropium Bromide inhibits the reaction [Oxotremorine results in increased expression of EDN1 mRNA] |
CTD |
PMID:22796455 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
Tiotropium Bromide results in decreased activity of PON1 protein |
CTD |
PMID:31581362 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion |
ISO |
Tiotropium Bromide results in decreased secretion of TNF protein |
CTD |
PMID:21352583 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
thiaton results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
thiaton inhibits the reaction [Indomethacin results in increased activity of MPO protein] |
CTD |
PMID:11855677 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
thiaton inhibits the reaction [Indomethacin results in increased activity of NOS2 protein] |
CTD |
PMID:11855677 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases transport |
ISO |
valspodar inhibits the reaction [ABCB1 protein results in increased transport of trospium chloride] |
CTD |
PMID:25466967 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
decreases activity increases metabolic processing |
ISO |
trospium chloride results in decreased activity of SLC22A1 protein SLC22A1 protein results in increased metabolism of trospium chloride |
CTD |
PMID:25466967 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
decreases activity |
ISO |
trospium chloride results in decreased activity of SLC22A2 protein |
CTD |
PMID:25466967 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases metabolic processing decreases activity |
ISO |
SLCO1A2 protein results in increased metabolism of trospium chloride trospium chloride results in decreased activity of SLCO1A2 protein; trospium chloride results in decreased activity of SLCO1A2 protein alternative form |
CTD |
PMID:25466967 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
decreases activity |
ISO |
trospium chloride results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25466967 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 protein] |
CTD |
PMID:30036686 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 protein] |
CTD |
PMID:30036686 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM1 protein] |
CTD |
PMID:9846649 |
|
NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM2 protein] |
CTD |
PMID:9846649 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM3 protein] |
CTD |
PMID:9846649 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM4 protein] |
CTD |
PMID:9846649 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM5 protein] |
CTD |
PMID:9846649 |
|
NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 8:55,401,981...55,415,012
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 PMID:16931985 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein] |
CTD |
PMID:16931985 |
|
NCBI chr 1:116,715,286...116,837,223
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 PMID:16931985 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] |
CTD |
PMID:16931985 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 protein] |
CTD |
PMID:31846720 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 protein] |
CTD |
PMID:30959089 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 protein] |
CTD |
PMID:29486207 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:29486207 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Hdac4 |
histone deacetylase 4 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 protein] |
CTD |
PMID:31846720 |
|
NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164
|
|
G |
Hexb |
hexosaminidase subunit beta |
increases secretion |
ISO |
Vecuronium Bromide results in increased secretion of HEXB protein |
CTD |
PMID:19758318 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
increases expression multiple interactions |
ISO |
Vecuronium Bromide results in increased expression of HSD11B2 mRNA; Vecuronium Bromide results in increased expression of HSD11B2 protein Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 protein] |
CTD |
PMID:29486207 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:29486207 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:29486207 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 protein] |
CTD |
PMID:30036686 |
|
NCBI chr 1:95,041,967...95,047,377
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 protein] |
CTD |
PMID:30036686 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 protein] |
CTD |
PMID:30036686 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR protein] |
CTD |
PMID:31846720 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|